Hammond Janet MJ
SEC insider (Form 3/4/5 filer). CIK 0001829899. Chief Development Officer at Atea Pharmaceuticals, Inc. (AVIR). 6 reported Form 4/5 transactions since Sep 2024; latest on Jan 31, 2026. Located in BOSTON, MA.
Companies Hammond Janet MJ has filed insider reports for
- Atea Pharmaceuticals, Inc. (AVIR): Officer, Chief Development Officer
Hammond Janet MJ
CIK: 0001829899
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Atea Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect58.1K shares- - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
Tax PaymentDirect14.1K shares at avg. $4.24$60K - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
AwardDirectStock Option (Right to Buy)
177K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect46.8K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
AwardDirect11.3K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
Tax PaymentDirect14.1K shares at avg. $3.06$43K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 58,050 | - | $0 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment | 14,136 | $4.24 | $59,937 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Award Stock Option (Right to Buy) | 177,000 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 46,800 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award | 11,250 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment | 14,134 | $3.06 | $43,250 | Direct |
1-6 of 6 transactions